Osmotica Pharmaceuticals
OverviewSuggest Edit
Osmotica Pharmaceutical is a fully-integrated pharmaceutical company specializing in osmotic drug delivery. The Company possesses a diversified product portfolio in the specialty neurology and women's health space, including five promoted products and approximately 35 non-promoted products, several of which incorporate the proprietary Osmodex® drug delivery system. The non-promoted product portfolio includes methylphenidate HCl ER tablets and venlafaxine HCl ER tablets and prescription and non-prescription dietary supplements.
| Type | Public | |
| Founded | 2000 | |
| HQ | Bridgewater, US | Map |
| Website | osmotica.com | |
| Employee Ratings | More |
Recent NewsAll News
- Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors
- Osmotica Pharmaceuticals plc Announces Results of Extraordinary General Meeting
- Osmotica Pharmaceuticals plc to Provide Second Quarter 2019 Business and Financial Update on August 8, 2019
- Osmotica Pharmaceuticals plc to Present at Jefferies 2019 Global Healthcare Conference
Key People/Management at Osmotica Pharmaceuticals
David Burgstahler
Sriram Venkataraman
Osmotica Pharmaceuticals Office Locations
Osmotica Pharmaceuticals Financials and Metrics
Osmotica Pharmaceuticals Revenue
| USD | |
|---|---|
Revenue (Q3, 2019) | 65.5m |
Gross profit (Q3, 2019) | 38.1m |
Gross profit margin (Q3, 2019), % | 58.3% |
Net income (Q3, 2019) | (112.7m) |
EBIT (Q3, 2019) | (123.0m) |
Market capitalization (21-Feb-2020) | 343.7m |
Closing stock price (21-Feb-2020) | 5.9 |
Cash (30-Sept-2019) | 98.0m |
EV | 517.5m |
| USD | Y, 2019 |
|---|---|
EV/EBIT | -4.2 x |
EV/CFO | 15.7 x |
Financial Leverage | 3.5 x |
Osmotica Pharmaceuticals Revenue Breakdown
Osmotica Pharmaceuticals revenue breakdown by business segment: 9.4% from Lorzone, 7.8% from Divigel, 40.4% from Venlafaxine ER, 18.4% from Methylphenidate and 24.0% from Other
Osmotica Pharmaceuticals Online and Social Media Presence
Osmotica Pharmaceuticals's Trends
Osmotica Pharmaceuticals News and Updates
Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors
Osmotica Pharmaceuticals plc Announces Results of Extraordinary General Meeting
Osmotica Pharmaceuticals plc to Provide Second Quarter 2019 Business and Financial Update on August 8, 2019
Osmotica Pharmaceuticals plc to Present at Jefferies 2019 Global Healthcare Conference
Osmotica Pharmaceuticals plc to Present at 2019 RBC Capital Markets Global Healthcare Conference
Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 (“RVL”) for Acquired Blepharoptosis (ptosis or droopy eyelid)
Osmotica Pharmaceuticals Frequently Asked Questions
When was Osmotica Pharmaceuticals founded?
Osmotica Pharmaceuticals was founded in 2000.
Who are Osmotica Pharmaceuticals key executives?
Osmotica Pharmaceuticals's key executives are David Burgstahler and Sriram Venkataraman.
How many employees does Osmotica Pharmaceuticals have?
Osmotica Pharmaceuticals has 466 employees.
What is Osmotica Pharmaceuticals revenue?
Latest Osmotica Pharmaceuticals annual revenue is $263.7 m.
What is Osmotica Pharmaceuticals revenue per employee?
Latest Osmotica Pharmaceuticals revenue per employee is $565.9 k.
Who are Osmotica Pharmaceuticals competitors?
Competitors of Osmotica Pharmaceuticals include Horizon Therapeutics, Esperion Therapeutics and Vitality Biopharma.
Where is Osmotica Pharmaceuticals headquarters?
Osmotica Pharmaceuticals headquarters is located at 400 Crossing Blvd, Bridgewater.
Where are Osmotica Pharmaceuticals offices?
Osmotica Pharmaceuticals has offices in Bridgewater, Marietta, Sayreville, Tampa and in 4 other locations.
How many offices does Osmotica Pharmaceuticals have?
Osmotica Pharmaceuticals has 8 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies